JPRN-UMIN000005877CompletedPhase 2
Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancer - ECD
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Toho University
- Enrollment
- 43
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) patient who has drug allergy as past history 1. Known hypersensitivity to DOC, NDP and Polysorbate-80 2. patient who has active infectious disease 3. patient who has active double cancer 4. patient who has severe complication (interstitial pneumonitis, DM etc.) 5.concomitant treatment with steroids 6.EDEMA 7. patient who want to be pregnant and /or pregnant woman 8. patient who was judged to be unsuitable for this clinical trial
Investigators
Similar Trials
Completed
Phase 2
A randomized phase 2 study of Docetaxel with or without Bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced non-squamous non-small-cell lung canceron-small cell lung cancerJPRN-UMIN000004715West Japan Oncology Group100
Active, not recruiting
Phase 1
A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolone plus Zoledronic Acid plus Strontium-89 in Hormone Refractory Prostate Cancer metastatic to bone. - TRAPEZE: phase II/III efficacy and safety clinical trial in Hormone Refractory Prostate CancerHormone refractory Prostate Cancer (HRPC)EUCTR2004-002295-41-GBThe University of Birmingham757
Recruiting
Not Applicable
A Multicenter phase II study of Docetaxel combined with Bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000009966Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University20
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270